Divani Caravel Hotel Athens...multicenter phase II trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in first-line

www.bsabcs.gr

Greece2017

13 - 14 January 2017Divani Caravel Hotel

A t h e n s

Under the auspices of

Organized by

13 - 14 January 2017Divani Caravel HotelAthens


03

Welcome addressDear Colleagues,

The Organizing Committee of the San Antonio Breast Cancer Symposium (SABCS), and the Cretan Association of Biomedical Research welcomes you to “Best of SABCS - Greece 2017”, the 2nd edition of Best of SABCS to be held in Greece.

The SABCS, now in its 39th year, is the premier conference for basic, translational, and clinical cancer research professionals. It is well known for presenting the latest breast cancer data from all over the world.

The Best of SABCS allows professionals, who are unable to travel to San Antonio, the opportunity to experience and discuss the research and advances with colleagues and key opinion leaders.

Attendees to the Best of SABCS program will receive the most current information on breast cancer research presented in the original format delivered at the meeting in San Antonio in December 2016. You will learn of the current advances in breast cancer research that are changing clinical practice for the benefit of patients.

Principal subject areas of the “Best of SABCS - Greece 2017” program include:

• Advances in the basic and translational research of breast cancer

• Latest research on systemic therapy of early breast cancer and treatments for advanced breast cancer

• Updates in surgery and radiation therapy

• A comprehensive review of the studies reported in 2016 on every field of breast cancer research

The SABCS has always been a forum for interaction between individuals involved with all aspects of breast cancer research and care and it is envisioned that this camarade-rie will also be experienced at “Best of SABCS - Greece 2017”.

We would like to extend recognition and thanks to the supporters of the Best of SABCS: Hellenic Society for Medical Oncology, Hellenic Society of Breast Surgeons, Hellenic Society of Surgical Oncology, Hellenic Society for Therapeutic Radiation Oncology and Hellenic Oncology Research Group, for realizing the importance of education and who make it possible to bring this meeting to Greece.

On behalf of the organizing committee of the SABCS, and the Cretan Association of Biomedical Research, we would like to wish you fruitful conference.

Vassilis Georgoulias Emeritus Professor of Medical OncologySchool of Medicine, University of CretePresident of Cretan Association of Biomedical Research

σελ. 18-1918-19

Emmanouil Saloustros Medical OncologistGeneral Hospital of Heraklion“Venizelio”, Heraklion, Crete

20-21



05

Scientific Agenda

Friday 13 January 2017

17:00-17:05 Welcome and introduction V. Georgoulias

17:05-17:40 Session 1 Chairs: Ch. Emmanouilides, E. Lianidou

Speaker: G. Rigakos

S4-01. A novel BRD4 inhibitor enhances endocrine therapy efficacy and circumvents endocrine-resistance in estrogen receptor-positive breast cancer models.

S4-02. The Y537S ESR1 mutation is a dominant driver of distant ER-positive breast cancer metastasis.

Speaker: A. Koumarianou

S4-03. Targeted and selective degradation of estrogen receptor (ER) alpha by PROTACs.

S6-04. The PI3K inhibitor, taselisib, has enhanced potency in PIK3CA mutant models through a unique mechanism of action.

S4-06. Biological effects of abemaciclib in a phase2 neoadjuvant study for postmenopausal patients with hormone receptor positive, HER2 negative breast cancer.

17:40-18:15 Session 2 Chairs: G. Fountzilas, H. Kourea

Speaker: P. Economopoulou

S1-08. Prognostic associations of tumor-infiltrating lymphocytes (TIL) in metastatic HER2-positive breast cancer (BC) treated with trastuzumab and pertuzumab: A secondary analysis of the CLEOPATRA study.

S1-09. Evaluation of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarker in different subtypes of breast cancer treated with neoadjuvant therapy - A meta-analysis of 3771 patients.

Discussant: E. Razis: Should TIL information be included in the pathology report?

18:15-18:30 Coffee break



07

18:30-19:10 Session 3 Chairs: D. Pectasides, A. Kotsakis

Speaker: N. Pistamaltzian

S1-07. Immune sculpting of the triple negative breast cancer genome.

S1-01. Whole exome and transcriptome sequencing of resistant ER+ metastatic breast cancer.

S1-10. Clinical implications of somatic mutations in post-menopausal early-stage estrogen receptor (ER)-positive HER2-negative breast cancer (BC): Results from the BIG 1-98 study.

Discussant: K. Papazisis: Sequencing breast cancers: ready for prime time?

19:10-20:00 Session 4 Chairs: V. Barbounis, I. Boukovinas

Speaker: N. Tsoukalas

S5-01. DCIS biological risk profile predicts risk of recurrence after breast conserving surgery in a Kaiser Permanente NW population.

S4-04. Tumor microenvironment of metastasis (TMEM) score is associated with early distant recurrence in hormone receptor (HR) positive, HER2-negative early stage breast cancer (ESBC).

Speaker: A. Tzovaras

S6-05. Comprehensive comparison of prognostic signatures for breast cancer in TransATAC.

S3-03. PAM50 intrinsic subtype as a predictor of pathological complete response following neoadjuvant dual HER2 blockade without chemotherapy in HER2-positive breast cancer: First results of the PAMELA clinical trial.

Discussant: A. Nikolaidi: Molecular signatures in breast cancer

20.00 A w a rd fo r l i f e t i m e a c h i e v e m e n t i n b re a s t c a n c e r c a re



09

Saturday 14 January 2017

09:00-09:45 Session 5 Chairs: A. Ardavanis, I. Drositis

Speaker: V. Ramfidis Greek studies and worth discussing posters I.

Speaker: M. Nikolaou Worth discussing posters II.

09:45-10:20 Session 6 Chairs: H. Linardou, I. Mountzios

Speaker: A. Markou

S3-01. IMENEO: International MEta-analysis of circulating tumor cell detection in early breast cancer patients treated by NEOadjuvant chemotherapy.

S3-02. Plasma microRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: Results from Neo-ALTTO.

Discussant: E. Lianidou: Circulating biomarkers in breast cancer.

10:20-11:15 Session 7 Chairs: V. Venizelos, M. Kontos

Speaker: H. Faliakou

Worth-discussing posters III (focus on locoregional treatment of early breast cancer)

Speaker: S. Lanitis

S3-07. Impact of radiotherapy on complications and patient-reported satisfaction with breast reconstruction: Findings from the prospective multicenter MROC study.

S3-08. Radioactive seed localization versus wire guided localization of nonpalpable invasive and in situ breast cancer: A Danish multicenter randomized controlled trial.

S2-07. Sentinel node detection after neoadjuvant chemotherapy in patient without previous axillary node involvement (GANEA 2 trial): Follow-up of a prospective multi-institutional cohort.

Discussant: I. Sanidas: Evaluation and management of axilla in early breast cancer.

Organized by



1110

11:15-11:30 Coffee break

11:30-12:40 Session 8 Chairs: Ch. Kourousis, Ch. Panopoulos

Speaker: V. Voulgaris

S2-01. Breast cancer risks associated with mutations in cancer predisposition genes identified by clinical genetic testing of 60,000 breast cancer patients.

S2-03. Does BRCA status affect outcome in young breast cancer patients? Results from the prospective study of outcomes in sporadic and hereditary breast cancer (POSH).

Speaker: G. Lypas

S2-02. The landscape of somatic genetic alterations in BRCA1 and BRCA2 breast cancers.

S6-01. BRCA1 methylation status, silencing and treatment effect in the TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012).

S2-04. RANK ligand as a target for breast cancer prevention in BRCA1 mutation carriers.

Speaker: F. Stavridi

S2-05. Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: A randomized, phase 2 study.

S2-06. DNA repair deficiency biomarkers and MammaPrint high1/(ultra)high2 risk as predictors of veliparib/carboplatin response: Results from the neoadjuvant I-SPY 2 trial for high risk breast cancer.

Discussant: D. Tryfonopoulos: BRCA1/2 and breast cancer: implications for treatment and prevention.

12:40-13:15 Session 9 Chairs: Ch. Christofyllakis, N. Androulakis

Speaker: M. Theoxari

S3-05. Integrated analysis of multidimensional genomic data on CALGB 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer.

S3-06. A phase III trial evaluating pCR in patients with HR+, HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) +/- estrogen deprivation: NRG oncology/NSABP B-52.

Discussant: A. Koutras: Neoadjuvant chemotherapy for HER2-positve breast cancer.

13:15-14:10 Session 10 Chairs: N. Kentepozidis, I. Karaitianos

Speaker: E. Lianos

S1-03. First results from the multicenter phase III DATA study comparing 3 versus 6 years of anastrozole after 2-3 years of tamoxifen in postmenopausal women with hormone receptor-positive early breast cancer.

S1-04. Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006-05).

S1-05. A randomized, double-blinded, placebo-controlled clinical trial to evaluate extended adjuvant endocrine therapy (5 years of letrozole) in postmenopausal women with hormone-receptor positive breast cancer who have completed previous adjuvant endocrine therapy: Initial results of NRG oncology/NSABP B-42.

Speaker: M. Bakogeorgos

S6-03. DBCG 07-READ: A randomized phase III trial comparing six cycles of docetaxel and cyclophosphamide (DC) to three cycles of epirubicin and cyclophosphamide followed by three cycles of docetaxel (EC-D) in patients with early breast cancer.

S6-07. Double blinded validation study to assess performance of IBM artificial intelligence platform Watson for oncology in comparison with Manipal multidisciplinary tumour board--First study of 638 breast cancer cases.

Discussant: Ch. Christodoulou: Optimal duration of systemic treatment for early breast cancer.

14:10-15:00 Lunch break



1312

15:00-15:40 Session 11 Chairs: S. Kαkolyris, N. Ziras

Speaker: E. Kontopodis

S3-04. Primary analysis of PERTAIN: A randomized, two-arm, open-label, multicenter phase II trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in first-line patients with HER2-positive and hormone receptor-positive metastatic or locally advanced breast cancer.

S1-02. PrECOG 0102: A randomized, double-blind, phase II trial of fulvestrant plus everolimus or placebo in post-menopausal women with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC) resistant to aromatase inhibitor (AI) therapy.

S4-07. BELLE-3: A Phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2-, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment.

Discussion: A. Alexopoulos: Optimizing hormonal treatment for metastatic breast cancer.

15:40-16:30 Session 12 Chairs: P. Kosmidis, Ch. Kalofonos

Speaker: P. Katsaounis

S5-03. Menopausal symptoms as predictors of long-term adherence in the International breast cancer intervention study (IBIS-1).

S5-06. Randomized, placebo-controlled trial of duloxetine for aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS) in early stage breast cancer (SWOG 1202).

Speaker: S. Peroukidis

S5-07. Aromatase inhibitors and endothelial function: Is there an association with early cardiovascular disease?

S6-02. The efficacy and safety of the addition of ibandronate to adjuvant hormonal therapy in postmenopausal women with hormone-receptor positive early breast cancer. First results of the TEAM IIB trial (BOOG 2006-04).

Discussant: E. Timotheadou: Hormonal therapy: not as simple as a pill.

16:30-17:10 Session 13 Chairs: Ch. Papadimitriou, I. Athanasiadis

Speaker: S. Karageorgopoulou

S5-02. Scalp Cooling Alopecia Prevention trial (SCALP) for patients with early stage breast cancer

S5-04. Low-fat dietary pattern and breast cancer overall survival in the women’s health initiative dietary modification randomized controlled trial.

S5-05. Impact of pre-operative exercise on breast cancer gene expression.

Discussant: F. Poulakaki: Life-style modification adjuvant therapy.

17:10-18:10 Session 14: 2016 in review. Chairs: I. Varthalitis, Α. Polyzos

Speaker: N. Xenidis Best of the year 2016: translation research

Speaker: H. Galani Early breast cancer

Speaker: Z. Saridaki Advanced breast cancer

18:15 Closing Remarks



14

Lypas G. MD, Associate Director, 1st Dpt. of Medical Oncology, “Hygeia” Hospital, Athens

Markou A. Postdoctoral Researcher, Lab of Analysis Circulating Tumor Cells (ACTC Lab), Dpt. of Chemistry, University of Athens, Athens

Mountzios I. MD,MSc, PhD, 251 Airforce General Hospital, Athens

Nikolaidi A. MD, Associate Director, Dpt. of Medical Oncology, “Mitera” Clinic, Athens

Nikolaou M. MD, MSc, PhD, Dpt. of Internal Medicine, “Hippokratio” General Hospital of Athens, Athens

Panopoulos Ch. MD PhD, Head, Dpt. of Medical Oncology at Euroclinic Group, Athens

Papazisis K. MD, Euromedica General Clinic of Thessaloniki, Thessaloniki

Papadimitriou Ch. Professor of Medical Oncology, Medical School, National and Kapodistrian University of Athens, Athens

Pectasides D. Professor of Medical Oncology, Director, 2nd Dpt. of Internal Medicine, University of Athens, School of Medicine, “Hippokration” University Hospital of Athens, Athens

Peroukidis P. MD, MSc, PhD, University Hospital of Patras, Patra

Pistamaltzian N. MD, PhD, Dpt. of Medical Oncology, “Mitera” Hospital, Athens

Polyzos A. Emeritus Professor of Medical Oncologist, National & Kapodistrian University of Athens, Athens

Poulakaki F. MD, PhD, FEBS, Chief, Dpt. of Breast Surgery, “Metropolitan” Hospital, Pireaus

Ramfidis V. MD, MSc, Consultant, Dpt. of Medical Oncology, 251 Airforce General Hospital of Athens

Razis E. MD, PhD, Director, 3rd Oncology Dpt., Hygeia Hospital, Director Contemporary Oncology Team, Athens

Rigakos G. MD, MSc, Consultant, 3rd Oncology Dpt. of “Hygeia” Hospital and the Contemporary Oncology Team, Athens

Saloustros E. MD, DSc, Oncology Unit, “Venizeleio” General Hospital of Heraklion, Heraklion

Sanidas I. MD, FACS, Breast surgeon, former Asst. Professor of Surgery, School of Medicine, University of Crete, Heraklion

Saridaki Z. MD, PhD Scientific Director, Oncology Dpt., “Asklepios”, Heraklion

Stavridi F. MD, Consultant, “Hygeia” Hospital, Athens

Theohari M. MD, Consultant, Oncology Unit, “Hippokrateion” University Hospital of Athens, Athens

Timotheadou E. Assistant Professor of Medical Oncology, Aristotle University of Thessaloniki, Thessaloniki

Tryfonopoulos D. Consultant , Athens Anti-Cancer Hospital “Agios Savvas”, Athens

Tsoukalas N. MD, MSc, PhD, MSc in Bioinformatics, Consultant at Veterans Hospital (417 NIMTS), Athens

Tzovaras A. MD, PhD, “Hippokratio” General Hospital of Athens, Athens

Varthalitis I. MD, Head, 1st Oncology Clinic, “Henry Dunant” Hospital Center, President of Hellenic Society of Medical Oncology (HeSMO)

Venizelos V. MD, Director, Breast Service, Dpt. of Surgery, “Metropolitan” Hospital, Pireaus

Voulgaris V. Consultant, 424 Military Hospital, Thessaloniki

Xenidis N. Assistant Professor of Clinical Oncology, Democritus University of Thrace, Alexandroupolis

Ziras N. MD, PhD, Head, Medical Oncology Dpt., “Metaxa” Cancer Hospital, Athens

AffiliationsAlexopoulos A. MD, PhD, “Hygeia” Hospital, Athens

Androulakis N. MD, PhD, Head, Oncology Unit, General Hospital of Heraklion “Venizeleio”, Heraklion

Ardavanis A. MD, Director, 1st Dpt. of Medical Oncology, Athens Anti-Cancer Hospital “Agios Savvas”, Athens

Athanasiadis I. MD, Director, Dpt. of Oncology, “Mitera” Hospital, Athens/Adjunct Assistant Professor, North-western University, Feinberg School of Medicine Hem/Onc. Division, USA

Bakogeorgos M. MD, Oncology Clinic, 251 General Airforce Hospital, Athens

Barbounis V. MD, Director, 3rd Dpt. of Medical Oncology, “Metropolitan” Hospital, Pireaus

Boukovinas I. MD, PhD, PharmaD, Head, Oncology Unit, “Bioclinic” Thessaloniki

Christodoulou Ch. MD, Director, 2nd Oncology Dpt., “Metropolitan” Hospital, Athens

Christofyllakis Ch. Director, Dpt. of Medical Oncology, 401 General Military Hospital of Athens, Athens

Drositis I. MD, PhD, Medical Oncology Unit, General Hospital of Heraklion “Venizeleio”, Heraklion

Economopoulou P. MD, PhD, “Attikon” Universtity Hospital, Athens

Emmanouilides Ch. MD, PhD, Professor, Dpt. of Hematology & Medical Oncology, UCLA, CA, USA, & European Interbalkan Medical Center, Thessaloniki

Faliakou H. MD, Breast Surgeon, Head, 2nd Breast Unit, “Mitera” Hospital, Athens

Fountzilas G. Professor Emeritus of Medical Oncology, Aristotle University of Thessaloniki, Thessaloniki

Galani H. MD, Deputy Director, Dpt. of Medical Oncology, “Metropolitan” Hospital, Pireaus

Georgoulias V. Emeritus Professor of Medical Oncology, School of Medicine, University of Crete, Heraklion

Kakolyris S. MD, PhD, Professor and Head, Dpt. of Clinical Oncology, Medical School, University of Thrace, Alexandroupolis

Kalofonos Ch. Professor of Medical Oncology, General University Hospital of Patras, Patra

Karageorgopoulou S. MD, Dpt. of Μedical Oncology, IASO, Athens

Karaitianos I. Associate Professor of Surgery, Athens University, Chairman of the Dpt. of Surgical Oncology, Agios Savvas Cancer Hospital, Athens

Katsaounis P. MD, 1st Oncology Unit, IASO General, Athens

Kentepozidis N. MD, Head, Oncology Clinic, 251 General Airforce Hospital, Athens

Kontopodis E. MD, General Hospital of Heraklion “Venizeleio”, Heraklion

Kontos M. MD, PhD, Associate Professor of Surgery and Breast Surgery, National and Kapodistrian University of Athens

Kosmidis P. MD, Director, 2nd Dpt. of Medical Oncology, “Hygeia” Hospital, Athens

Kotsakis A. Assistant Professor of Medical Oncology, University Hospital of Heraklion & Laboratory of Transla-tional Oncology, University of Crete, School of Medicine, Heraklion

Koumarianou A. MD, PhD, Consultant, 4th Dpt. of Internal Medicine, Attikon University Hospital, Athens

Kourea H. Associate Professor, Division of Clinical Laboratories, Dpt. of Pathology, University of Partas, Greece

Kourousis Ch. MD, Head, Dpt. of General Clinic “IASO”, Chania

Koutras A. Assistant Professor of Medical Oncology, University of Patras, Patra

Lanitis S. Consultant, Breast, Endocrine and Minimal Invasive Surgery, 2nd Surgical Dpt. and Unit of Surgical Oncology “Korgialenio – Benakio”, Red Cross Hospital, Athens

Lianidou E. PhD, Professor of Analytical Chemistry - Clinical Chemistry, Laboratory of Analysis of Circulating Tumor Cells, Dpt. of Chemistry, University of Athens, Athens

Lianos E. MD, Consultant, Dpt. of Medical Oncology, “Metaxa” Memorial Cancer Center Hospital, Piraeus

Linardou H. MD, PhD, Ass. Director, Consultant Medical Oncologist, A’ Oncology Dpt., Metropolitan Hospital, Athens

15



Επιστηµον ικές Εκδηλώσε ις & Εκτυπώσε ις Ε∆ΡΑ ∆α ιδάλου 10 , Ηράκλε ιο Κρήτης 71202 Τηλ . 2810 222155 Fax 2810 222156

ΥΠΟΚΑΤΑΣΤΗΜΑ Κλεοµένους 7 , Κολωνάκ ι 10675 Αθήνα Τηλ. 210 7240039, 210 7240608 Fax 210 7240139 Ε-mai l in fo@scep .gr www.scep.gr

S c i e n t i f i c I C u l t u r a l E v e n t s & P u b l i c a t i o n s

Notes

17



22

General InformationOrganized by

Symposium Venue Divani Caravel Hotel, 2 Vasileos Alexandrou Str., 16121, Athens T: 210 7207000

Under the aupsices of:

Registration Fees Free

Official Language The official language of the meeting is Greek.

Certificate of attendance Based on the latest circular of the National Drug Organization the Event is required to use an attendance tracking system. All registered participants will receive name badges, which they are kindly requested to wear at all times. Each badge will have a barcode for monitoring the hours of attendance.

By the end of the event a certificate will be given to those who have attended at least 60% of the total hours of the scientific Program. The number of credits of Continuing Medical Education (CME-CPD) to be administered to the participants will be calculated on the basis of monitoring time.

The event has been awarded by Panehellenic Medical association (PIS) with 8 CME - CPD credits

Symposium Secretariat

Scientific | Cultural Events and Publications T +30 210 7240039 F +30 210 7240139 E [email protected] www.scep.gr

Sponsors

Documents

Divani Caravel Hotel Athens...multicenter phase II trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in first-line